

Get the latest Macrobid shortage update for 2026. Learn what's causing the Nitrofurantoin supply issues, when it may improve, and what to do now.
The Macrobid (Nitrofurantoin) shortage continues to affect patients across the United States in early 2026. If you rely on this antibiotic for UTI treatment or prevention, here's everything you need to know about the current situation.
As of February 2026, Macrobid and generic Nitrofurantoin remain in limited supply at many pharmacies nationwide. The shortage is not uniform — some pharmacies have adequate stock while others have been out for weeks. The situation varies by region, pharmacy chain, and formulation.
The FDA's Drug Shortage Database continues to list Nitrofurantoin as a medication with supply concerns. Several generic manufacturers have reported intermittent production and shipping delays.
The current shortage is driven by multiple overlapping factors:
Several Nitrofurantoin manufacturers have faced production challenges, including equipment maintenance, facility upgrades, and FDA compliance inspections. With only a handful of companies producing the drug in the US market, any single disruption has an outsized effect on supply.
The active pharmaceutical ingredient (API) for Nitrofurantoin is sourced from a limited number of global suppliers. Ongoing supply chain pressures — including shipping delays and increased regulatory requirements — have slowed the flow of raw materials to manufacturers.
UTI prescribing has shifted in recent years. As medical guidelines increasingly recommend against fluoroquinolones (like Ciprofloxacin) for uncomplicated UTIs due to serious side effects, demand for first-line agents like Nitrofurantoin and Trimethoprim-sulfamethoxazole has increased. For more background, see our article on why Macrobid is so hard to find.
The shortage primarily affects:
Availability varies by formulation. In some areas, one version may be available even when others are not. Ask your pharmacist about all available forms.
There's no definitive end date for the Macrobid shortage. The FDA is working with manufacturers to increase production, and some companies have reported progress in resolving their supply chain issues. Industry analysts suggest that availability may begin to stabilize by mid-to-late 2026, but this is not guaranteed.
Drug shortages can be unpredictable. New disruptions — a factory shutdown, a regulatory issue, or a spike in demand — can extend a shortage beyond initial projections.
It's tempting to ask for extra refills, but hoarding medications makes the shortage worse for everyone. Only fill the amount your doctor prescribes.
MedFinder helps you find pharmacies that currently have Macrobid in stock. Check it regularly, as stock levels change daily. See our detailed guide on how to find Macrobid in stock near you.
Don't just check your regular pharmacy. Try independent pharmacies, grocery store pharmacies (Kroger, H-E-B, Publix), big-box stores (Costco, Walmart), and mail-order pharmacies.
If Macrobid is unavailable, talk to your doctor about alternative antibiotics for UTIs. Options like Bactrim, Fosfomycin, and Cephalexin may be more readily available.
UTIs should be treated promptly. If you can't find Macrobid, contact your doctor the same day. An untreated UTI can progress to a kidney infection, which is much more serious and may require hospitalization.
Some patients take low-dose Nitrofurantoin (50-100 mg) daily as UTI prophylaxis. If you're in this group and can't find your medication:
Do not stop taking a prescribed medication without talking to your doctor first.
Bookmark this page — we update it as new information becomes available. You can also check these resources:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.